Chronic lung disease (CLD) in premature newborns is associated with increased concentrations of inflammatory cytokines in tracheal aspirates (TA). We determined if polymorphisms of cytokine genes influence the risk of developing CLD by genotyping 178 mechanically ventilated very low birth weight (VLBW) infants for the tumor necrosis factor-a (TNF-a) À308 G/A, transforming growth factor-b 1 (TGF-b 1 ) +915 G/C and monocyte chemoattractant protein-1 (MCP-1) À2518 A/G polymorphisms. Genomic DNA was isolated from TA and genotypes determined by restriction length polymorphism. There was no effect of any of these polymorphisms on the development of CLD (29 vs 23%, P ¼ 0.371, TNF-a À308 AA/AG vs TNF-a À308 GG; 23 vs 26%, P ¼ 0.681, MCP-1 À2518 GG/AG vs MCP-1 À215-8 AA; 24 vs 24%, P ¼ 0.978, TGF-b 1 +915 CG vs TGF-b 1 +915 GG). TA IL-8 and MCP-1 concentrations were not different between genotype groups. Infants with the TNF-a À308 A allele had increased risk of IVH (RR 2.07; 95% CI 1.02-4.18, P ¼ 0.041) and infants with the TGF-b 1 +915 C allele were at greater risk of death (32 vs 9%, P ¼ 0.016). These data suggest that these polymorphisms do not play a significant role in determining risk for CLD in preterm infants, but may play a role in other complications in the neonatal period.
Introduction
Despite significant improvements in neonatal intensive care, chronic lung disease (CLD) remains a long-term complication of mechanical ventilation (MV) of preterm infants. Increased concentrations of inflammatory mediators in airway secretions during the first week of life have been associated with the development of CLD in the preterm infant suggesting that inflammation plays a central role in this condition. [1] [2] [3] [4] [5] [6] [7] [8] Concentrations of tumor necrosis factor-a (TNF-a), a central mediator in the inflammatory cascade, are elevated during the first week of life in the tracheal aspirates (TA) obtained from infants who subsequently develop CLD. 1, 2 The magnitude of TNF-a production may be in part genetically determined. A biallelic (G-A) polymorphism at position À308 in the TNF-a-promotor region confers either high (A) or low (G) gene transcription in vitro. [9] [10] [11] [12] The TNF À308 A allele has been associated with the development or increased severity of several lung diseases. [13] [14] [15] Transforming growth factor-b 1 (TGF-b 1 ), a multifunctional cytokine that regulates differentiation and proliferation of fibroblasts, is produced by many cell types in the lung. Increased expression of TGF-b 1 has been implicated in the development of lung fibrosis in both animal models and human disease. [16] [17] [18] A role for TGF-b 1 in the development of CLD in the preterm newborn is suggested by the finding of increased concentrations in TA fluid of infants who develop this complication. 7 Several polymorphisms have been described for the TGF-b 1 gene. [17] [18] [19] [20] The polymorphism (G-C) located within exon 1 at codon 25 (915 bp downstream of the start point) is associated with decreased production of TGF-b 1 in vitro (C allele). This polymorphism is associated with an increased frequency of lung fibrosis and a more rapid decline of lung function in patients with cystic fibrosis. [17] [18] [19] [20] Recruitment of mononuclear cells to the lung and their subsequent activation is an important pathological feature of lung fibrosis and is regulated by chemotactic cytokines such as monocytes chemoattractant protein-1 (MCP-1). 21 MCP-1 has been implicated in the pathogenesis of chronic inflammatory lung diseases that have a fibrotic component. [21] [22] [23] [24] [25] Consistent with a role for MCP-1 in the development of chronic lung injury in the newborn are the observations that TA MCP-1 concentrations increase during acute lung injury in preterm infants and correlate with the development of CLD. 6 A polymorphism (A-G) occurs in the distal regulatory region of the MCP-1 gene 2518 bp upstream from the transcription start site and results in increased MCP-1 in vitro (G allele). 26 The role of this polymorphism in the development of lung disease has not been extensively studied. A recent study has shown that an increase in the frequency of asthma was associated with the G allele. 27 The reasons for the differences in cytokine production in infants and the subsequent development of CLD are not completely understood and are undoubtedly multifactorial. Differences in ventilation strategies, lung maturity, pre-and postnatal infections, nutritional status and genetic factors (presumably) interact in the development of CLD. As a result of the intimate relation between inflammation and the development of CLD, cytokines and/or their receptors are good candidate genes to alter risk in this population.
The aim of this study was to determine if there was an association between the TNF À308, TGF-b 1 +915 and MCP-1 À2518 polymorphisms, and the development of CLD in very low birth weight (VLBW) neonates undergoing MV.
Results
A total of 178 patients had complete clinical information on respiratory outcome and suitable DNA extracted from the archived TA pellet. TA pellets had been stored from 6 months to 5 years before processing. Mean gestational age and birth weight of the study population were 26.9 7 0.2 weeks and 927 7 17 g, respectively. All patients had required MV at birth and 168 (94%) infants were treated with exogenous surfactant therapy (Survanta s , Ross Products Division, Abbott Laboratories, Columbus, OH, USA). TA cultures obtained during the first few days of life grew Ureaplasma urealyticum (Uu) on at least one occasion from 48 of 161 infants cultured (27%). In all, 92 (52%) infants were oxygen dependent at 28 days and 39 (22%) were oxygen dependent at 36 weeks postconceptional age (PCA). There were 20 (11%) patients who died during their initial hospitalization (17 before 28 days of age and 3 after 28 days).
The TNF-a À308 promoter polymorphism was successfully determined in all patients. One patient (each) could not be genotyped for the MCP-1 À2518 and TGF-b 1 +915 polymorphisms.
TNF-a À308 promoter polymorphism and outcome The frequency of the A allele (associated with higher TNF-a production in vitro) in the study population was 0.17. Of the 178 patients studied, 124 (70%) were homozygous GG, nine (5%) were homozygous AA and 45 (25%) were heterozygous (AG). As a result of the low number of AA homozygotes, AA and AG patients were combined into a single group for further analysis. Baseline clinical characteristics of birth weight, gestational age, need for surfactant replacement therapy and rates of isolation of Uu from the airway were not different between groups (Table 1) . The TNF-a À308 G/A polymorphism did not significantly alter the risk of CLD in VLBW infants who required MV at birth. There were no differences in the incidence of O 2 dependency at either 28 postnatal days or 36 weeks PCA between infants with and without the TNF-a À308 A allele (Table 2) . Additionally, the combined outcomes of death or CLD, duration of O 2 therapy, and duration of MV were not different between groups.
Infants with the TNF-a À308 A allele had a significantly increased risk of IVH of all grades (RR 2.07; 95% CI 1.02-4.18, P ¼ 0.041). However, the risk for severe IVH (Grades 3 and 4) or other neonatal complications was not increased ( Table 3 ). The TNF-a À308 A allele did not influence TA cytokine concentrations measured in our study population. Maximum TA interleukin-18 (IL-8) (2371 7 1002 pg/mg secretory component (Sec) vs 481 7 123 pg/mg Sec, P ¼ 0.075) and MCP-1 (4797 7 1543 pg/mg Sec vs 4745 7 2611 pg/mg Sec, P ¼ 0.991) concentrations were not different in the subset of patients studied between those with the TNF-a À308 A allele (n ¼ 21) or without (n ¼ 59).
MCP-1 À2518 polymorphism and outcome
The frequency of the G allele (associated with higher MCP-1 production in vitro) in the study population was 0.18. Of the 177 patients successfully genotyped, 112 Cytokine polymorphisms and chronic lung disease in neonates K Adcock et al (63%) were homozygous AA, six (3%) were homozygous GG and 59 (33%) were heterozygous (GA). As a result of the low number of GG homozygotes, GG and GA patients were combined into a single group for further analysis. Birth weight, gestational age, need for surfactant replacement therapy and rates of isolation of Uu from the airway were not different between groups (Table 4 ). Similar to the results seen for the TNF-a À308 A/G polymorphism, the MCP-1 À2518 polymorphism did not significantly alter the risk of CLD in VLBW infants who required MV at birth. There were no differences in the incidence of O 2 dependency at either 28 postnatal days or 36 weeks PCA between infants with and without the MCP-1 À2518 G allele (Table 5) . Additionally, the combined outcomes of death or CLD, duration of O 2 therapy, duration of MV were not different between groups. Further, the risk for other neonatal complications was not increased (Table 6 ). Maximum TA IL-8 (1044 7 581 vs 933 7 292 pg/mg Sec, P ¼ 0.852) and MCP-1 (6506 7 3195 vs 2027 7 752 pg/mg Sec, P ¼ 0.272) concentrations were not different in the subset of patients studied between those with the MCP-1 À2518 G allele (n ¼ 48) or without (n ¼ 32).
TGF-b 1 +915 polymorphism and outcome
The frequency of the C allele (associated with lower TGFb 1 production in vitro) in the study population was 0.079. Of the 177 patients studied, 149 (84%) were homozygous GG and 28 (16%) were heterozygous (CG). There were no homozygous CC patients. Birth weight, gestational age, need for surfactant replacement therapy and rates of isolation of Uu from the airway were not different between groups (Table 7) . Similar to the results seen for the other two polymorphisms studied, the MCP-1 À2518 polymorphism did not significantly alter the risk of CLD in VLBW infants who required MV at birth. There were no differences in the incidence of O 2 dependency at either 28 postnatal days or 36 weeks PCA between infants with and without the TGF-b 1 +915 C allele ( Table  8 ). The combined outcome of CLD or death, duration of O 2 therapy and duration of MV were not different between groups. However, infants with the C allele were significantly at greater risk of dying during their initial hospitalization (32 vs 9%, P ¼ 0.016). Most of the differences were accounted for by the increase in the risk of early death (death before 28 days of age) ( Table 8 ).
The risk for other neonatal complications was not increased (Table 9) . Maximum TA IL-8 (1304 7 721 vs 908 7 318 pg/mg Sec, P ¼ 0.605) and MCP-1 (3516 7 1666 vs 5036 7 2394 pg/mg Sec, P ¼ 0.768) concentrations were not different in the subset of patients studied between those with the TGF-b 1 +915 C allele (n ¼ 14) or without (n ¼ 66). 
Discussion
Inflammation and increased TA concentrations of many cytokines are associated with the development of CLD in the preterm neonate. [1] [2] [3] [4] [5] [6] [7] [8] Since inflammation is a fundamental pathologic feature of CLD, the genetic variants of cytokine genes may be good candidates to explain some of the individual variation in the development of this complication.
TNF-a is a central mediator in the inflammatory cascade and TA concentrations are elevated in infants who develop CLD.
1,2 Of the numerous polymorphisms described in the TNF-a locus, we examined the À308 G/ A polymorphism because of its effect on in vitro TNF-a production and the previously described associations of the À308 A variant with several lung diseases. Furthermore, the frequency of the A allele was expected to be large enough in our study population to impact on disease progression.
In our study population, the À308 A allele was not associated with the development of CLD, and/or death suggesting that factors other than genetic variation at this locus contribute to these outcomes. The frequency of the À308 A allele (0.17) was somewhat higher than expected for a largely African-American population. The frequency of the À308 A allele in European Caucasians ranges from 18 to 27%. 20, [28] [29] [30] [31] The frequency of the À308 A allele is lower in those of African descent (10%). 31, 32 Possible explanations for this observation are that the À308 A allele increases risk for preterm delivery, or increases need for MV at birth, or both. Indeed, preliminary reports suggest a role for this polymorphism in the etiology of preterm births. 33, 34 TNF-a stimulates IL-8 and MCP-1 production in lung cells. There was a trend for IL-8 (but not MCP-1) to be higher in patients with the À308 A allele. Again, this suggests that factors other than the À308 polymorphism determine the magnitude of the cytokine response in the lung of preterm infants undergoing MV. TA TNF-a concentrations were not measured in our study population, so it is possible that there is a direct effect on TNF-a production in the infants.
The TNF-a À308 A allele was associated with an increased risk of IVH but not severe IVH in this study. This suggests a potential role for TNF-a in the etiology of this complication. This observation is consistent with the mounting evidence that proinflammatory cytokines are important mediators in perinatal brain injury. 35 Hypoxia and ischemia, which are known to contribute to the pathogenesis of IVH, are associated with upregulation of TNF-a. 36 It is reasonable to suggest that preterm infants with the À308 A allele have increased TNF-a production when exposed to a perinatal brain insult and thus a greater risk for intraventricular bleeding.
Recently, we reported the association of increased TA MCP-1 concentrations and the development of CLD in this population. 6 The À2518 A/G polymorphism in the distal regulatory region of the MCP-1 gene results in increased MCP-1 in vitro. 26 The role of this polymorphism in human disease has not yet been widely studied, but an increase in frequency of asthma was associated with the À2518 G allele. 27 In our study population, the À2518 G allele was not associated with the development of CLD, and/or death suggesting that factors other than genetic variation at this locus contribute to these outcomes. The frequency of the À308 G allele (0.18) was in agreement with other published data. The frequency of the MCP-1 À2518G allele in Caucasians is 29% with a lower frequency in African Americans (22%). 26 There was no effect of the À2518 polymorphism on TA MCP-1 or IL-8 concentrations in MV preterm infants. Again, this suggests that factors other than this polymorphism are important in determining the pulmonary inflammatory response in these patients.
TGF-b 1 is a multifunctional cytokine that regulates differentiation and proliferation of fibroblasts. In addition to its profibrotic role, TGF-b 1 has anti-inflammatory actions. TGF-b 1 concentrations are increased in TA obtained from preterm infants who develop CLD as in other types of lung fibrosis. 7, [16] [17] [18] [19] Increased production of TGF-b 1 in vitro increased risk for lung fibrosis and decline in lung function in cystic fibrosis is associated with the more common +915 G allele. [18] [19] [20] In our study population, TGF-b 1 +915 G/C polymorphism was not associated with an altered risk for the development of CLD suggesting that factors other than genetic variation at this locus contribute to these outcomes. However, the risk of early death was greatly increased in infants with the +915 C allele. Additionally, the frequency of the +915 C allele (0.079) was lower than expected in our study population. The frequency of the +915C allele is reported to be 0.08-0.10 in Caucasians and 0.12 in those of African descent. [18] [19] [20] The reasons for this lowered frequency of the C allele are not obvious from this study, but may reflect a survival disadvantage for fetuses at risk for preterm delivery, a decreased incidence of prematurity or a decreased need for ventilation at birth. In addition, the low frequency of the C allele greatly increases the chance of a type 2 error.
In addition to the +915 G/C polymorphism, two other polymorphisms of the TGF-b 1 gene (+869 T/C and insertion of C at +72) are associated with an increased frequency of fibrotic lung disease. [18] [19] [20] We have not yet studied these polymorphisms and it is quite possible that they influence outcome in ventilated preterm infants.
The observations of this retrospective case controlled study are limited by selection bias. This is especially true for outcomes other than CLD. Since only infants who were mechanically ventilated were included, the true impact of these polymorphisms on the complications of prematurity may be underestimated. Ethnicity greatly influences the distribution of gene polymorphisms. 35 Therefore, caution should be taken not to extrapolate our findings to other ethnically different populations. Cytokine polymorphisms and chronic lung disease in neonates K Adcock et al
Finally, lung injury and the subsequent maladaptive repair process that leads to the development of CLD is complex with a great many factors that interplay to determine outcome. It is very likely that genetic differences other than cytokine gene polymorphisms play a role in determining risk of poor outcome. Polymorphisms in other cytokines, their receptors, bacterial pattern recognition molecules, surfactant proteins, angiotensin converting enzyme and heme oxygenase-1 are known to alter the course of other pulmonary diseases and should be examined as to their potential role in the development of CLD in the VLBW infant.
In summary, the TNF-a À308 G/A, MCP-1 À2518 A/G and TGF-b 1 +915 G/C polymorphisms have little or no influence on the development of CLD in ventilated VLBW infants. The association of the TNF-a À308 A allele and risk of IVH are intriguing and needs to be confirmed by additional studies. Additional research into the genetic determinants of CLD in the preterm infant is needed.
Methods
This is a retrospective, case controlled study that utilized archival TA pellets from earlier studies of cytokine concentrations as a source of genomic DNA. Infants were included in the study if they fulfilled the following inclusion criteria: birth weight less than 1500 g, MV during the first week of life, complete clinical data on pulmonary outcome and a stored TA pellet that could be used for genotyping. Infants were excluded if complete data on pulmonary outcome were not available or suitable DNA could not be extracted from the TA pellet. The study was approved by the Institutional Review Board for Human Research at Louisiana State University Health Sciences Center in Shreveport.
TA were originally collected as part of a long-term longitudinal studies examining cytokine concentrations and the development of CLD. Serial aspirates were obtained at intervals during the first 21 days of life while the infant remained on MV as previously described. 6 Cultures for genital mycoplasmas were performed on samples collected in the first few days of life. The TAs were centrifuged 14 000 g for 10 min and the supernatant and pellets were frozen at À201C until assayed for cytokines by enzyme linked immunosorbent assay (ELISA) or DNA extracted for genotype analysis.
Clinical and outcome data were abstracted from the clinical record and included information on respiratory outcome, survival and development of complications of prematurity.
Laboratory methods
Isolation of total DNA from the TA pellets was performed using the QIAmp DNA Mini kits TM (Qiagen Incorporated, Chatsworth, CA, USA). Briefly, TA pellets were suspended in 200 ml of sterile phosphate-buffered saline by vigorous vortexing, then digested in proteinase K and applied to silica gel spin columns. Columns were washed in the manufacturer's supplied buffers and the total DNA was eluted in 200 ml elution buffer. PCR was performed using the PCR Core System (Promega, Madison, WI, USA).
Genotyping of TNF-a À308 promoter region polymorphism Genotyping the TNF-a À308 promoter region polymorphism was performed using a technique that introduces a NcoI restriction site into PCR products at the site where the polymorphism occurs. 9 Primers for this reaction were: forward 5 0 -AGG CAA TAG GTT TTG AGG GCC AT-3 0 and reverse 5 0 -TCC TCC CTG CTC CGATTC CG-3 0 . 25-50 ng of total DNA was amplified by PCR in a 25 ml reaction mixture containing 1.5 mM MgCl 2 , 50 mM KCl, 200 mM dNTPs, 500 nM primers and 1.25 U Taq polymerase. PCR reactions were run at 941C for 5 min, followed by 40 cycles consisting of melting at 941C for 3 min, annealing at 601C for 1 min, and extension at 721C for 1 min. PCR amplifications included a final extension step at 721C for 10 min to insure full-length transcripts. PCR products were digested with NcoI (Promega) overnight at 371C. PCR products and restriction enzyme (RE) digests were visualized on ethidium bromide-stained 10% polyacrylamide gels. Patients homozygous for the G allele have an NcoI restriction site in the PCR products and therefore have two bands of 87 and 20 bp, patients homozygous for the A allele will have a single uncut 107 bp product and heterozygotes have all three bands.
Genotyping of MCP-1 À2518 distal regulatory region polymorphism Genotyping the MCP-1 promoter region polymorphism was accomplished by PCR amplification of genomic DNA using primers that span the polymorphic region followed by restriction analysis. 27 Primers for this reaction were: forward 5 0 -TCT-CTC-ACG-CCA-GCA-CTG-ACC-3 0 and reverse 5 0 -GAG-TGT-TCA-CAT-AGG-CTT-CTG-3 0 . 25-50 ng of total DNA was amplified by PCR in a 25 ml reaction mixture containing 1.5 mM MgCl 2 , 50 mM KCl, 200 mM dNTPs, 50 nM primers and 1.25 U Taq polymerase. Cycling parameters consisted of an initial melting at 941C for 1 min followed by 40 cycles of 941C for 1 min, annealing at 62.51C for 1 min, and extension at 721C for 1.5 min. PCR amplifications included a final extension step at 721C for 10 min to insure full-length transcripts. PCR products were digested by treatment with PvuII (Promega) for 2 h at 371C. PCR products and RE digests were visualized as above. Patients homozygous for the G allele have a PvuII restriction site in the PCR products and have two bands of 159 and 75 bp, patients homozygous for the A allele have a single 234 bp product and heterozygotes have all three bands.
Genotyping of the TGF-b 1 +915 polymorphism Genotyping the TGF-b 1 +915 polymorphism was accomplished by PCR amplification of genomic DNA using primers that span the polymorphic region followed by restriction analysis. 37 Primers for this reaction were: forward 5 0 -TTC-CCT-CGA-GGC-CCT-CCT-A-3 0 and reverse 5 0 -GCC-GCA-GCT-TGG-ACA-GGA-TC-3 0 . 25-50 ng of total DNA was amplified by PCR in a 25 ml reaction mixture containing 1.5 mM MgCl 2 , 50 mM KCl, 200 mM dNTPs, 500 nM primers, 0.1% Tween 20 and 1.25 U Taq polymerase. Cycling parameters were: initial melting at 961C for 10 min, followed by 35 cycles of melting at 961C for 1 min, annealing at 621C for 1 min and extension at 731C for 1 min. PCR reactions included a final extension step at 731C for 10 min. PCR products were digested with BglI (Promega) for 2 h at 371C. BglI digestion yields 131, 103 and 60 bp fragments in patients homozygous for the G allele, 163 and 131 bp fragments in patients homozygous for the C allele, and all four fragments in heterozygotes.
TA cytokine determination
Concentrations of IL-8, MCP-1 and secretory component (Sec) in TA samples were determined using ELISA as previously described. 6 Data analysis Statistical analysis was performed using SPSS for Windows version 6.0 (SPSS Inc., Chicago, IL, USA). w 2 analysis was used to assess the statistical differences in categorical variables. The Student's t-test was used to assess normally distributed variables. The data are presented as mean 7 s.e. of the mean (s.e.m). A twotailed P-value o0.05 was considered significant.
The primary end point for this study was the development of CLD or death. Several definitions of CLD in the newborn are commonly used. [38] [39] [40] Both oxygen dependency at 28 days with a compatible chest X-ray and oxygen dependency at 36 weeks PCA predict long-term adverse outcomes. 40 As a result of this, cytokine genotypes were correlated to both of these outcomes.
TA concentrations were analyzed in a subset of patients to determine if there was a correlation between genotype and cytokine response. Some of these patients have been reported in earlier studies. 6 Since the timing of the inflammatory response varied between patients, we correlated maximal TA IL-8 and MCP-1 concentrations in the first week of life to genotype. Patients were included in this subset analysis, if there were cytokine measurements for at least the first 5 days of life. To adjust for variation in collection of TA, IL-8 and MCP-1 concentrations were normalized to secretory component. 32 
